Previous 10 | Next 10 |
ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deu...
2023-07-13 10:18:09 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) gained ~6% in the morning hours Thursday after Bank of America upgraded the maker of Orladeyo hereditary angioedema (HAE) therapy, citing a recent selloff in company shares. The analyst Tazeen Ahmad raises his ...
2023-06-27 12:11:27 ET Shares of Pharvaris N.V. (NASDAQ: PHVS) were up more than 10% at 11:30 a.m. on Tuesday, a day after the Food and Drug Administration (FDA) lifted a clinical hold on an individual new drug (IND) application for Pharvaris' therapy to treat hereditary angioedema ...
2023-06-27 10:07:53 ET Gainers: Black Diamond Therapeutics ( BDTX ) +91% . Cara Therapeutics ( CARA ) +27% . Pharvaris ( PHVS ) +21% . AC Immune ( ACIU ) +11% . Immix Biopharma ( IMMX ) +6% . Losers: Adicet Bio ( ACET ...
2023-06-26 12:05:01 ET Shares of Swiss biotech Pharvaris ( NASDAQ: PHVS ) were up 13% in midday trading Monday following news that US regulators had lifted a clinical hold on testing for its proposed treatment for hereditary angioedema, or HAE. Pharvaris said the US Food and Dru...
ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the...
2023-06-20 07:04:01 ET Pharvaris ( NASDAQ: PHVS ) has entered into a private placement offering relating to the offer and sale of an aggregate of 6,951,340 ordinary shares to a group of institutional investors at $10.07 per share, for gross proceeds of approximately $70 million. ...
ZUG, Switzerland, June 20, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated i...
2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo ZUG, Switzerland, June 11, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage...
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...
2024-06-02 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...